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Reduced tubular cation transport in diabetes: Prevented by situated in the basolateral membrane of proximal tubular
ACE inhibition. cells. In the rat kidney, organic cation transporters (OCTs)
Background. The renal clearance of organic cations is im- situated in the S1 and S2 segments (OCT-1) and in S2 andportant for the homeostasis of a number of exogenous and
S3 segments (OCT-2) of the proximal tubule are responsi-endogenous compounds. The organic cation transporters (OCTs)
ble for the first step in active cation secretion [1–3]. OCTssituated on the basolateral surface of proximal tubular cells
are necessary for the renal clearance of a broad range ofmediate active cation excretion. Alterations of cation transport
may occur in diabetes, although the role of the OCTs has not substrates, including drugs (e.g., metformin,  blockers),
been previously assessed. toxins, and xenobiotics. OCTs are also important for the
Methods. Experimental diabetes was induced in rats with renal homeostasis of a number of endogenous compounds,streptozotocin (55 mg/kg) and animals were randomly assigned
including monoamine neurotransmitters, N-methyl-nico-to receive ramipril (3 mg/mL) in drinking water for 24 weeks.
tinamide (NMN), creatinine, choline, cortisol, and pros-In a second protocol, rats were infused with angiotensin II
taglandins (PGE2, PGF2-) [2–5].(Ang II) at a dose of 58.3 ng/kg/min for 2 weeks via an im-
planted osmotic pump. Expression of the OCTs and renal clear- Diabetic nephropathy is characterized by early impair-
ance of the endogenous cation N-methyl-nicotinamide (NMN) ment of proximal tubular function with disruption of
was assessed. tubular acidification [6] and lysosomal degradation [7].
Results. Diabetes was associated with a reduction in gene
However, the effect of diabetes on OCT is unclear. Re-and protein expression of both OCT-1 and OCT-2 and a reduc-
duced accumulation of cationic nephrotoxins (includingtion in NMN clearance. These effects were prevented by rami-
cephalordine [8] and cisplatin [9] in experimental diabe-pril, associated with the prevention of albuminuria and tubular
injury as demonstrated by the expression of osteopontin and tes) has been attributed to impaired transporter path-
glutathione peroxidase 3 (GPX-3). An infusion of Ang II also ways, contributing to “renal protection” in these models.
reduced NMN clearance but without altering the renal expres- Ex vivo studies using renal cortical slices have provided
sion of OCTs.
conflicting data, demonstrating both reduced [9], un-Conclusion. We hypothesize that reduced expression of
changed [10], or even increased cation transport in dia-OCTs in diabetes may be a marker of tubular injury. However,
betic animals [11]. These ambiguous results may repre-Ang II may also directly augment renal cation clearance inde-
pendent of changes in transporter expression. Together these sent the limitations of slice studies in the evaluation of
effects may provide additional mechanism to explain treat- solely basolateral cation uptake, particularly in an in
ment-related improvements in creatinine clearance and reno- vivo context. Given the clinical importance of the cationprotection in diabetes following blockade of the renin-angio-
transporter system, we have undertaken to examine thetensin system (RAS).
expression and regulation of OCTs in diabetic nephropa-
thy. Furthermore, we explored the link of cation trans-
port to the renin-angiotensin system (RAS), a pathwayTransepithelial clearance of small cationic molecules
that has been implicated in pathogenesis of progressiveis mediated in the kidney by electrogenic transporters
tubulointerstitial injury in experimental diabetes.
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weeks and weighing between 200 and 250 g were used rate (GFR) was measured by a single-injection isotopic
technique [99technetium-diethylenetriaminepenta-aceticin this study. The protocols for animal experimentation
acid (99Tc-DTPA)] developed in our laboratory [16].and the handling of animals were in accordance with the
After 24 weeks of experimental diabetes or 2 weeks ofprinciples established by the Animal Welfare Committee
Ang II infusion, rats were culled by decapitation. Theof the Austin and Repatriation Medical Centre.
kidneys were rapidly dissected out and bisected, with one
Experimental diabetes model half snap-frozen in liquid nitrogen and stored at 80C
prior to use and the other half embedded in paraffin.Experimental diabetes was induced by intravenous in-
jection of the beta cell toxin streptozotocin (Sigma Chemi-
Microarraycal Co., St. Louis, MO, USA) at a dose of 55 mg/kg fol-
RNA isolation. Frozen kidneys from 24-week controllowing an overnight fast. Animals with a plasma glucose
(N  10) and diabetic (N  10) rats were homogenizedconcentration in excess of 15 mmol/L 1 week after the
(Polytron, Kinematica AG, Lucerne, Switzerland) andinduction of diabetes were included in the study as diabetic
total RNA isolated according to the Trizol protocol(N 20). Sham-injected control animals (sodium citrate
(Gibco BRL, Grand Island, NY, USA). RNA samplesbuffer, pH 4.5) were followed concurrently (N  20).
were treated with RNAse-free DNAse (Gibco BRL).Diabetic and control animals were randomized to receive
RNA quality was assessed by formaldehyde gel electro-ramipril (Aventis, Frankfurt, Germany) in drinking water
phoresis to ensure that all samples used were of equiva-at a dose of 3 mg/L for diabetic rats and 9 mg/L for control
lent quality based on the 18S:28S ratio. Ten microgramsrats for 24 weeks. In addition, diabetic animals were
of RNA from all control and diabetic animals was pooledgiven 2 units of Ultralente insulin (Ultratard HM, Novo
to obtain 100 g RNA for each group. The RNA wasIndustries, Bagsvaerd, Denmark) daily to maintain body
then treated with DNase (DNA-free reagent, Ambion,weight and prevent ketoacidosis without significantly
Austin TX, USA) as per manufacturer’s recommenda-lowering blood glucose levels. Each was given an identi-
tions before storage at –70C.cal diet (Barrastoc GR2 rat and mouse breeder ration,
Labeling and hybridization reaction. A total of 5 gClayton, Victoria, Australia) that included supplemental
of pooled and DNase-treated RNA were used in eachnicotinic acid (96 mg/kg). Throughout the study animals
labeling reaction. These were carried out in accordancewere given access to food and water ad libitum.
with instructions enclosed in the Array Advantage AA
labeling kit (Ambion). The platform used for gene pro-Chronic exposure to angiotensin II (Ang II) model
filing experiments was the Rat 1.2 Atlas Array Mem-
Chronic infusion of angiotensin II (Ang II) into nor- branes (BD Biosciences Clontech, Palo Alto, CA, USA).
mal rats results in tubulointerstitial injury associated with Briefly, the CDS primer mix (BD Biosciences Clontech)
moderate systolic hypertension [12]. In a second proto- was used to prime the synthesis of labeled cDNA. A
col, 14 male Sprague-Dawley rats were infused with ei- typical labeling reaction yield was between 5 and 20 
ther human Ang II (Auspep, Parkville, Victoria, Austra- 106 cpm. Hybridizations were carried out in 15 ml of
lia) at a dose of 58.3 ng/kg/min (N  7) or vehicle (0.15 hybridization buffer containing 0.4 106 cpm/mL at 50C
mol/L sodium chloride and 1 mmol/L acetic acid, N  7) for 16 hours. Membranes were washed at 50C for 2 
for 14 days using an Alzet osmotic minipumps (Model 30 minutes with 2  sodium chloride sodium citrate
2002, Alzet Corp., Cupertino, CA, USA) implanted sub- (SSC)  1% sodium dodecyl sulfate (SDS), followed by
cutaneously in the midscapular region, as previously de- 2  30 minutes with 0.5  SSC  1% SDS. Membranes
scribed [12]. were then exposed to phosphoimager plates for 3 days
before images were captured using a FujiBass 3000 phos-Measurement of physiologic and
phoimager (Fuji Medical Systems, Inc., Stanford, CT,biochemical parameters
USA). Experiments were repeated 6 times using the
The following parameters were serially measured: pooled RNA samples.
body weight; blood glucose, measured using a glucometer Data analysis. Membrane blots were analyzed using
(Accutrend; Boehringer Mannheim G.m.b.H. Biochem- Atlas Image software (BD Biosciences Clontech). Fol-
ica, Mannheim, Germany); systolic blood pressure, mea- lowing background correction and normalization using
sured by tail-cuff plethysmography in conscious, warmed the global sum method, data were exported to Microsoft
rats [13]; glycated hemoglobin, measured by high-perfor- Excel (Microsoft, Santa Rosa, CA, USA) for further
mance liquid chromatography (HPLC) (CLC330 GHb analysis.
Analyzer; Primus, Kansas City, MO, USA) [14]. Urine
Real-time reverse transcription-polymerase chainwas collected from animals that were placed in individual
reaction (RT-PCR)metabolic cages (Iffa Credo, L’Arbresele, France) for
24 hours for measurement of albumin excretion rate Expression of mRNA of OCT-1 and OCT-2 was as-
sessed with real-time quantitative reverse transcription-(AER) by radioimmunoassay [15]. Glomerular filtration
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Table 1. The influence of diabetes and ramipril on glomerularpolymerase chain reaction (RT-PCR) performed using
filtration rate (GFR), albuminuria, and blood pressure
the TaqMan system based on real-time detection of accu-
Systolicmulated fluorescence (ABI Prism 7700, Perkin-Elmer,
GFR Albuminuria blood pressureInc., PE Biosystems, Foster City, CA, USA). RNA was mL/min/kg mg/day mm Hg
extracted from animals as above. Genomic DNA con-
8 Weeks
tamination was removed by subjecting sample RNA to Control 9.8	0.3 0.8	0.1 136	3
Diabetes 13.2	0.4a 4	3a 137	3DNase treatment (Ambion). Three micrograms of RNA
Diabetes  ramipril 13.4	0.4 0.8	0.1b 119	2bwere used to synthesize cDNA with Superscript First
Control  ramipril 8.9	0.3 1.0	0.2 123	2
Strand Synthesis system for RT-PCR (Gibco BRL). 24 Weeks
Control 8.8	0.2 2	1 136	3Samples were further subjected to PCR amplification
Diabetes 14.6	0.5a 34	9a 140	3without a reverse transcriptase step to confirm the ab-
Diabetes  ramipril 14.1	0.6 3	1b 123	2b
sence of genomic DNA. Fluorescence for each cycle was Control  ramipril 7.8	0.6 3	1 124	2
quantitatively analyzed by an ABI Prism 7700 Sequence a Control vs. diabetes, P 
 0.001
b Diabetes vs. diabetes  ramipril, P 
 0.001Detection System (Perkin-Elmer, Inc.). To control for
variation in the amount of DNA available for PCR in
the different samples, gene expression OCTs were nor-
malized in relation to the expression of an endogenous
GPX-3 were prepared from rat cDNA and shortened bycontrol, 18S ribosomal RNA (rRNA) (18S rRNA Taq-
alkaline hydrolysis to an average length of 250 bases.Man Control Reagent kit; ABI Prism 7700, Perkin-Elmer
Purified probes were then cloned into pGemT easy vec-Inc.). Primers and TaqMan probe for OCTs and the
tor (Promega, Madison, WI, USA) and linearized withendogenous reference 18S rRNA were constructed with
Sal-1. Antisense riboprobes for OCTs were then gener-the help of Primer Express (ABI Prism 7700, Perkin-
ated using T7 RNA polymerase. Background hybridiza-Elmer Inc.).
tion was controlled for by the inclusion of a sense ribo-PCR amplification was done in a 25 L volume, in-
probe or treatment with RNAse prior to hybridization.cluding 1  TaqMan buffer A, 200 mol/L deoxyATP
Four micron sections were hybridized with riboprobes(dATP), 200 mol/L 32P deoxycytidimine triphosphate
and then exposed to BioMax MR film for 3 to 5 days.(dCTP), 200 mol/L deoxyGTP (dGTP), 400 mol/L
deoxyUTP (dUTP), 100 nmol/L fluorogenic probe, 200
Western blotnmol/L each of forward and reverse primers, 0.5 U uracil-
Renal tissue was homogenized and lysed in 50 mmol/LN-glycosylase, 1.25 U DNA polymerase (PE Biosys-
HEPES, pH 7.5, containing 150 mmol/L NaCl, 1.5 mmol/Ltems), and 100 ng sample cDNA. The forward primer
MgCl2, 1 mmol/L ethyleneglycol tetraacetate (EGTA), 10%for OCT-1 was 5-TGGTGTTTAGGCTGATGGAA-3
glycerol, 1% Triton X-100, 1 g/mL aprotinin, 1 g/mLand the reverse primer for OCT-1 was 5-GCCCAAAA
leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride, 200CCCCAAACAAA-3. The probe specific to OCT-1 was
mol/L orthovanadate. Samples were standardized forFAM-5–TTTGGCAAGCCCTGCCCTCA–TAMRA;
protein (BCA; Pierce, Rockford, IL, USA), solublizedFAM  6-carboxyfluorescein, TAMRA (quencher) 
in a reducing buffer containing 2% SDS, 125 mmol/L6-carboxy-tetramethylrhodamine. The forward primer
Tris-HCl, 20% glycerol, and 10% 2-mercaptoethanol andfor OCT-2 was 5-GCGAGCATGGCTGGGTATAC-3
heated at 100C for 5 minutes. Aliquots (40g) were thenand the reverse primer for OCT-2 was 5-CAGGT
were separated by electrophoresis using a 12% SDS-TAAACTCAGTGACAATGG-3. The probe specific
polyacrylamide gel electrophoresis (SDS-PAGE). Pro-to OCT-2 was FAM-5–ACACTCCCGGCTCC-3;-
tein was transferred to a polyvinylidine difluoride (PVDF)TAMRA. The amplification was performed with the fol-
membrane (Immobilon-P; Millipore, Bedford, MA, USA)lowing time course: 50C, 2 minutes and 10 minutes at
by semi-dry electroblotting and incubated with commer-95C; and 40 cycles of 94C, 20 seconds, 60C, 1 minute.
cial polyclonal OCT-1 and OCT-2 antibodies respec-Each sample was tested in triplicate. Results were ex-
tively (Alpha Diagnostics International, San Antonio,pressed as relative to control animals.
TX, USA) overnight at 4C at a dilution of 1:1000. Bound
In situ hybridization antibody was detected on x-ray film by enhanced chemi-
luminescence with a horseradish peroxidase-conjugatedThe site-specific expression of OCT-1 and OCT-2
antirabbit immunoglobulin G (IgG) antibody (1:2000)mRNA was determined by radioactive in situ hybridiza-
and Supersignal West Pico Chemiluminesent substratetion using methods carried out essentially as described
(Pierce, Rockford, IL, USA). Tubular injury was furtherelsewhere [17]. As a marker of proximal tubular injury
assessed by measurement of renal osteopontin expres-[18], renal expression of extracellular (also known as
sion [19], using commercially available antibody (Santa-plasma) glutathione peroxidase (GPX-3) was also as-
sessed. Briefly, cDNAs coding for OCT1, OCT-2, and Cruz Biotechnology, Santa Cruz, CA, USA). The relative
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Fig. 1. Microarray cDNA spots. Reduced ex-
pression of organic cation transporters (OCT)-1
(27%) (left panel) and OCT-2 (48%) (middle
panel) mRNA is shown in animals with diabe-
tes (pooled samples, N 10) compared to con-
trol (N  10). A 50% reduction in the expres-
sion of glutathione peroxidase 3(GPX-3) (right
panel) in diabetic kidney samples is shown as
a marker of tubular injury.
band size in each lane was determined densitometrically 1:50 for diabetic animals. N-ethyl-nicotinamide (NEN)
was added as an internal standard. Samples were deriva-using Optimax image systems (National Institutes of
tized using a condensation reaction with acetophenoneHealth, Bethesda, MD, USA), and compared to control
in NaOH at 0C, followed by dehydration in formic acidanimals which were accorded an arbitrary value of 1.
and subsequent formation of fluorescent 1,6-naphthyri-
Immunohistochemistry dine derivatives after heating samples at 110C for 3
minutes. The reaction mixture was then subjected toImmunohistochemical staining for OCT-1 and OCT-2
reverse-phase HPLC on a C18 column (Waters Divisionwas performed using commercial polyclonal antibodies
of Millipore, Marlborough, MA, USA) using a mobileto rat OCT-1 and OCT-2 (Alpha Diagnostics Interna-
phase (acetonitrile 18%, triethylamine 0.5%, 0.01 mol/Ltional). Briefly, antigen retrieval was performed using
sodium heptanesulfonate adjusted to pH 3.2), delivered0.4% pepsin (Sigma Chemical Co.) in 0.01 N hydrochlo-
isocratically at a flow rate of 1 mL/min at 50C. NMN andric acid for 5 minutes at 37C. Sections were washed and
NEN were detected at 4.5 and 5.8 minutes by fluorimetryblocked with 1% goat serum in 0.05% nonfat milk/Tris-
with excitation and emission wavelengths set at 366 andbuffered saline for 30 minutes before incubating with
418 nm, respectively. Fractional clearance of NMN wasrabbit antirat OCT-1 (1:500) or rabbit antirat OCT-2
calculated by dividing the body weight corrected renal(1:250) diluted in the blocking serum at 4C overnight.
NMN clearance by isotopically measured GFR. Net tu-Negative control slides were included without addition
bular NMN clearance was calculated by subtracting GFRof primary antibody. Vector biotinylated goat antirabbit
multiplied by plasma NMN concentration from totalimmunoglobulins was used as the secondary antibody
NMN clearance [i.e., tubular clearance  total NMNfollowed by Vector ABC (Vector Laboratories, Burl-
clearance – (GFR plasma NMN)] [20].
ingame, CA, USA). Peroxidase activity was identified by
reaction with 3,3-diaminobenzidine tetrahydrochloride Statistical analysis
tablets (Sigma Chemical Co.). Sections were counter- Data are expressed as means	 SEM unless otherwise
stained with haematoxylin dehydrated and mounted in stated. Normally distributed variables in different groups
DePeX (BDH, Melbourne, Australia). Tubular injury were compared by analysis of variance (ANOVA) using
was further assessed by measurement of tubular staining Microsoft Excel. Comparisons between group means
for osteopontin [19]. were performed by Fisher’s least significant difference
method. A P value of 
 0.01 was considered statisticallyMeasurement of NMN clearance
significant.
NMN is an endogenous cation that has been used as
a marker of tubular clearance [20, 21]. Urine and serum
RESULTSconcentrations of NMN were measured using HPLC
Animalsafter Musfield et al [21]. Briefly, urine and plasma were
deproteinated with 20% trichloroacetic acid. Urine was Animals with experimental diabetes had increased gly-
cated hemoglobin levels (13.6 	 0.7% vs. 4.2 	 0.2%,diluted 1:500 with 1 mmol/L HCI for control rats and
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Fig. 2. Expression of mRNA. (A ) Expression is shown for organic
cation transporters (OCT)-1 (left panel), OCT-2 (middle panel), and
glutathione peroxidase 3 (GPX-3) (right panel) in control animals (up-
per panel) and experimental diabetes (lower panel). (B ) Expression is
shown for OCT-1 (left panel), OCT-2 (middle panel), and GPX-3 (right
panel) in control animals (upper panel) and experimental diabetes
(lower panel).
P 
 0.01) and daily food (32 	 3 g/day vs. 21 	 1 g/day, vehicle (Ang II 199	 4 mm Hg; vehicle 135	 2 mm Hg,
P 
 0.001), although GFR was not significantly alteredP 
 0.01) and water intake (39 	 2 mL/day vs. 151 	 7
(Ang II 11.2 	 0.3 mL/min/kg; vehicle 11.7 	 0.2 mL/mL/day, P 
 0.01) compared to control animals (C)
min/kg, P  0.25). AER was also unaffected by Ang IIat 24 weeks. Neither glycated hemoglobin not feeding
infusion (Ang II 3 	 1; vehicle 5 	 2, P  0.65).behavior were significantly influenced by treatment with
ramipril (data not shown). The influence of ramipril on
Expression of OCT mRNAGFR, albuminuria, and blood pressure is shown in Table 1.
Notably, GFR was unaffected in the ramipril-treated Quantitative gene expression (measured by RT-PCR)
of cation transporters was variable, with standard errorsanimals from untreated probands, although blood pres-
sure was significantly reduced in all animals treated with of around 17% for both OCT-1 and OCT-2 expression.
Nonetheless, gene expression for both OCT-1 and OCT-2ramipril (vs. untreated, P 
 0.001, respectively).
In the Ang II infusion model, systolic blood pressure was significantly reduced in diabetic compared to con-
trols animals, demonstrated using microarray (Fig. 1),was increased following Ang II infusion compared to
Thomas et al: Renal cation transport in diabetes 2157
with previous reports [14] (Fig. 2 A and B). In situ studies
showed no change in the distribution of OCT-2 mRNA
in experimental diabetes; however, the reduced expres-
sion of OCT-1 in experimental diabetes was most marked
in the superficial cortical zones. This pattern of expres-
sion was identical to that of GPX-3, a known marker of
tubular injury (Fig. 2 A and B) [18]. The localization of
expression in ramipril-treated animals was not different
from control animals (data not shown).
Protein expression
Tubular immunostaining was specifically basal and lat-
eral for both OCTs (Fig. 4) consistent with previous
reports [1]. Again, OCT-1 was predominantly expressed
in the cortical S1 and S2 tubules and OCT-2 in the outer
stripe region with no tubular staining in the renal me-
dulla.
Protein expression for both OCT-1 and OCT-2 was
significantly reduced in diabetic kidneys (40%	 4% and
60 	 7%, respectively) on immunoblotting. Reduced
expression of both OCTs in diabetic animals was also
prevented by ramipril treatment (Figs. 4 and 5). As a
marker of tubular injury, expression of osteopontin was
increased in diabetic kidneys compared to control ani-
mals but normalized following treatment with ramipril.
Two-week Ang II infusion failed to significantly affect
the renal protein expression or distribution of either
Fig. 3. Renal expression of organic cation transporters (OCT)-1 OCT-1 and OCT-2 despite the presence of tubular injurymRNA (A) and OCT-2 (B) measured using real-time reverse transcrip-
as indicated by increased expression of osteopontin (Fig.tion-polymerase chain reaction (RT-PCR) in control animals (), dia-
betes (), and diabetes treated with ramipril ( ). Mean SEM. *Con- 4 and 5).
trol vs. diabetes, P 
 0.05; #Diabetes vs. diabetes  ramipril, P 
 0.05.
Measurement of NMN clearance
There was a significant reduction in renal cation clear-
ance in animals with diabetes as measured by the clear-real-time RT-PCR (Fig. 3), and in situ hybridization (Fig. 2
ance of the endogenous metabolite NMN. Serial clearanceA and B). This reduction in mRNA expression was great-
ratios in individual animals demonstrated a significantest in OCT-2 (51 	 6%) compared to OCT-1 (33 	 3%).
progressive decline in clearance at all time points in dia-Reduced tubular expression of OCTs in diabetic animals
betic animals with no significant change in control animals.was associated with a 50% reduction in mRNA levels of
By 24 weeks, tubular excretion of NMN was reduced byGPX-3, a marker of tubular injury.
over 60% in diabetic compared to control animals (0.6 	Treatment of diabetic animals with ramipril resulted in
0.1 mL/min vs. 1.6 	 0.2 mL/min, P 
 0.01). This effectnormalization of gene expression of both cation transport-
was completely attenuated by treatment with ramiprilers to control levels. Similarly, tubular expression of GPX-3
(Fig. 6). In animals treated with streptozotocin, in whomin diabetic animals was also normalized by treatment
diabetes failed to develop (glucose 
15 mmol/L, N with ramipril. Treatment of animals with Ang II failed
5), NMN clearance was no different to control animalsto produce any significant change in the renal mRNA
(1.7 	 0.4 mL/min vs. 1.6 	 0.2 mL/min). Tubular NMNlevels of either OCT-1 (1.0 	 0.1 vs. 1.0 	 0.1, P  0.94)
clearance was negatively correlated with degree of albu-or OCT-2 (1.2 	 0.2 vs. 1.1 	 0.1, P  0.43).
minuria at 24 weeks (R  0.56, P 
 0.001), although a
Localization of expression of OCT mRNA reduction in NMN clearance was apparent at 8 weeks
before the induction of significant proteinuria.In all tissues, OCT-1 mRNA was predominantly ex-
Despite not affecting the expression of OCTs, renalpressed in superficial cortical and juxtamedullary proxi-
tubular clearance of NMN was also reduced by 60%mal tubules. Expression of OCT-2 mRNA was higher in
following a 2-week Ang II infusion (1.0 	 0.2 mL/minthe juxtamedullary regions, particularly in the S2 and S3
tubules of the outer medulla (“outer stripe”) consistent vs. 0.4 	 0.1 mL/min, P 
 0.01).
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Fig. 4. Localization of renal expression. Expression of organic cation transporters (OCT)-1 protein (left panel), OCT-2 (middle panel), and
osteopontin (right panel) in control animals (top row), diabetes (second row), diabetes treated with ramipril (third row), and angiotensin-infused
animal (bottom row).
DISCUSSION this decline. In addition, reduced transporter function,
possibly mediated through Ang II, may influence theThis study demonstrates, for the first time, a progres-
diminished cation clearance seen in experimental dia-sive in vivo reduction of cation clearance in experimental
betes.diabetes, independent of GFR, yet associated with tubu-
The mechanism by which OCT expression is reducedlar injury. Significant reductions in gene and protein ex-
pression for both OCT-1 and OCT-2 may contribute to in experimental diabetes is unclear. It is possible that a
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Fig. 6. Tubular clearance of N-methyl-nicotinamide/glomerular filtra-
tion rate (NMN/GFR) in control animals (), diabetes (), and diabetesFig. 5. Immunoblot showing expression. Expression of organic cation treated with ramipril ().transporters (OCT)-1 protein (A ), OCT-2 (B ), and osteopontin (C ) in
control animals (left panel), diabetes (middle panel), and diabetes
treated with ramipril (right panel).
Ang II has an important role in renal proximal tubular
function, including acidification, fluid absorption [30],
reduction in OCT expression may simply be a marker and transporter activity, possibly through the induction
of tubular injury and its preservation by angiotensin- of protein kinase C (PKC) [31]. PKC is known to play
converting enzyme (ACE) inhibition may in part explain a pivotal role in the development of diabetic nephropa-
why cation transport was maintained in treated animals. thy and this effect is attenuated by ACE inhibition
Tubular cation transport is known to be impaired in [32, 33]. However, the role of PKC in the regulation of
other models of renal injury [22, 23]. The link with tubu- cation transport activity is controversial. Recent studies
lar injury is further suggested by the association with using human OCTs have shown inhibition of OCT-medi-
increased osteopontin expression [19] and reduced tubu- ated transport with activation of PKC [34]. But PKC-
lar expression of GPX-3 [18]. In our study, the rate of mediated phosphorylation of rat OCT-1 expressed in
deterioration of NMN clearance also correlated with al- HEK293 cells results in increased, rather than decreased,
buminuria, rather than GFR. This may not be surprising, substrate affinity and transporter activity [35]. Although
as significant tubular injury may occur in diabetes ne- we were unable to demonstrate any change in OCT ex-
phropathy before any change in GFR [16]. However, pression in animals infused with Ang II, the NMN clear-
reductions in both NMN clearance (shown here) and ance was significantly reduced. This is consistent with
OCT expression (unpublished results) may be apparent studies showing reduced cation accumulation following
before the onset of significant albuminuria. short-term exposure to Ang II in cell culture models [35].
Changes in steroid hormones, including testosterone The increase in cation transport in animals treated with
[24], oestradiolm and cortisol [25], that are known to ramipril may, therefore, in part be explained by altered
influence OCT expression, may also occur in diabetes transporter activity, mediated by Ang II and/or PKC.
[24, 26, 27]. Cation transport may be further reduced Homeostasis in the clearance of endogenous cation
in diabetes due to thickening and reduplication of the may be important for a number of reasons. In addition
tubular basement membrane [28], changes in tubular to drugs and toxins, monoamine neurotransmitters (in-
blood flow [21], and disruption of transepithelial poten- cluding noradrenaline, adrenaline, and dopamine) [3, 26],
tial [6]. Low bicarbonate (pH) and high lactate levels in corticosterone, and prostaglandins are cleared through
diabetic animals may affect substrate affinity by increas- these polyspecific tubular pathways [4, 5]. It is conceiv-
ing the fraction of protonated molecules in solution [29]. able that reduced tubular clearance in diabetes results
It is also possible that insulin may influence OCT expres- in “cation spillover” into the tubular circulation and en-
sion, as animals not treated with insulin for 8 weeks have hanced sensitivity, at least in the experimental (infusion)
a greater reduction in tubular NMN clearance (unpub- setting, to vasoconstrictors in diabetes [36]. Impaired
clearance of noradrenaline may also directly contributelished results).
In the present study, Ang II was also able to reduce to proteinuria in diabetes [37]. In addition, increased
medullary delivery of cortisol, prostaglandins, and cate-NMN clearance, independent of receptor expression.
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